Armata Pharmaceuticals, INC

Armata Pharmaceuticals announced significant progress in clinical, regulatory, and manufacturing for its AP-SA02 phage therapy, supporting a planned Phase 3 study initiation in late 2026.

Armata Pharmaceuticals announced the promotion of David House to Chief Financial Officer and updated employment terms for Pierre Kyme, effective July 17, 2026.

Armata Pharmaceuticals announced it has received agreement from the FDA on an Initial Pediatric Study Plan for AP-SA02, a key regulatory step for its Staphylococcus aureus bacteremia treatment.

Armata Pharmaceuticals has appointed Dr. Daniel Gilmer to its Nominating and Corporate Governance Committee.

Armata Pharmaceuticals shareholders re-elected seven board members and ratified the appointment of Ernst & Young LLP.

Armata Pharmaceuticals announced a $25 million secured credit agreement with Innoviva and reported its first quarter 2026 financial results, highlighting progress on its lead therapeutic candidate AP-SA02.

Armata Pharmaceuticals, Inc. reported its second quarter 2026 financial results, highlighting progress in its phage therapy development programs while acknowledging substantial doubt regarding its ability to continue as a going concern.

Armata Pharmaceuticals reported a significant net loss of $115.3 million in Q1 2026, raising substantial doubt about its ability to continue as a going concern despite positive clinical trial advancements and a new $25 million loan.

Armata Pharmaceuticals announced positive Phase 2a results for its lead bacteriophage candidate AP-SA02, but faces significant financial challenges with a going concern warning.

Armata Pharmaceuticals reports increased net losses and a going concern warning despite positive clinical trial results for its bacteriophage therapies.

Armata Pharmaceuticals announces its Q1 2025 financial results, highlighting ongoing clinical trials and a new $4.65 million funding boost for its AP-SA02 bacteremia program.

Armata Pharmaceuticals' Q3 2024 report shows a net loss of $5.481 million, but also highlights progress in clinical trials and a significant increase in grant revenue.

Armata Pharmaceuticals reports positive Phase 2a data for AP-SA02 in complicated S. aureus bacteremia, receives QIDP designation, and plans for Phase 3, but faces substantial doubt about its ability to continue as a going concern.

Armata Pharmaceuticals' 2024 10-K filing details clinical trial advancements, financial results, and strategic financing activities in the development of bacteriophage therapies.

Armata Pharmaceuticals has formalized a policy to recover incentive-based compensation from executives in the event of financial restatements.

Deborah Birx, Chief Executive Officer and a Director of Armata Pharmaceuticals, Inc., reported a transaction in 14,041 shares of common stock on July 10, 2026.

Armata Pharmaceuticals, Inc. director Daniel B. Gilmer reported the acquisition of stock options for 51,280 shares.

Armata Pharmaceuticals' Chief Business Officer, Pierre Kyme, reported the disposition of 1,030 common shares to cover tax liabilities related to restricted stock unit vesting.

Armata Pharmaceuticals CEO Deborah Birx reported the sale of 4,919 common shares to cover tax obligations related to restricted stock unit settlement.

Armata Pharmaceuticals Director Robin Kramer received a grant of 25,640 stock options with an exercise price of $11.61, vesting fully on March 9, 2027.

Armata Pharmaceuticals' Chief Business Officer, Pierre Kyme, was granted 183,142 stock options with an exercise price of $11.61, vesting over four years.

Armata Pharmaceuticals, Inc. has issued its proxy statement for the 2026 Annual Meeting of Shareholders, scheduled for June 11, 2026, detailing proposals for director elections, executive compensation, and auditor ratification.

Armata Pharmaceuticals will hold its 2025 Annual Meeting of Shareholders on June 12, 2025, to elect directors, approve executive compensation, and ratify the selection of its independent auditor.

Armata Pharmaceuticals announces its 2024 Annual Meeting of Shareholders to be held on June 12, 2024, to elect directors, approve executive compensation, and ratify the selection of Ernst & Young LLP as the company's auditor.

Innoviva, Inc. has expanded its financial commitment to Armata Pharmaceuticals through a new $25 million secured credit agreement.

Armata Pharmaceuticals, Inc. and Innoviva, Inc. have extended maturity dates for several credit agreements and expiration dates for warrants and a voting agreement, solidifying their financial relationship.

Innoviva, Inc. and its subsidiary have increased their beneficial ownership in Armata Pharmaceuticals to 83.3% and provided a new $15 million secured loan.

Innoviva, Inc. and its subsidiary have provided Armata Pharmaceuticals with a new $10 million secured loan and extended the maturity dates of three existing credit agreements to March 2026, solidifying their beneficial ownership to 85.2%.